UBP 302

Pricing Availability   Qty
Description: Potent and selective kainate antagonist; active enantiomer of UBP 296 (Cat. No. 2078)
Chemical Name: (S)-1-(2-Amino-2-carboxyethyl)-3-(2-carboxybenzyl)pyrimidine-2,4-dione
Purity: ≥98% (HPLC)
Citations (3)
Literature (3)

Biological Activity for UBP 302

UBP 302 is a potent and selective GluK1 (formally GluR5)-subunit containing kainate receptor antagonist (apparent KD = 402 nM); active enantiomer of UBP 296 (Cat. No. 2078). Displays ~ 260-fold selectivity over AMPA receptors, ~ 90-fold selectivity over recombinant human GluK2 (formally GluR6) and GluK5 (formally KA2)-containing kainate receptors and has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers. Also protects against soman-induced seizures and neuronal degeneration for up to 30 days when administered one hour after soman exposure.

Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.

Compound Libraries for UBP 302

UBP 302 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for UBP 302

M. Wt 333.3
Formula C15H15N3O6
Storage Store at RT
Purity ≥98% (HPLC)
CAS Number 745055-91-8
PubChem ID 6420161
Smiles O=C(C=CN(C[C@H](N)C(O)=O)C2=O)N2CC1=CC=CC=C1C(O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for UBP 302

Solvent Max Conc. mg/mL Max Conc. mM
1eq. NaOH 8.33 25
DMSO 6.67 20 with gentle warming

Preparing Stock Solutions for UBP 302

The following data is based on the product molecular weight 333.3. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.25 mM 12 mL 60.01 mL 120.01 mL
1.25 mM 2.4 mL 12 mL 24 mL
2.5 mM 1.2 mL 6 mL 12 mL
12.5 mM 0.24 mL 1.2 mL 2.4 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for UBP 302

Certificate of Analysis / Product Datasheet
Select another batch:

References for UBP 302

References are publications that support the biological activity of the product.

More et al (2004) Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47 46 PMID: 15165833

Dolman et al (2005) Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J.Med.Chem. 48 7867 PMID: 16302825

Apland et al (2014) The Limitations of D.pam as a Treatment for Nerve Agent-Induced Seizures and Neuropathology in Rats: Comparison with UBP302. J.Pharmacol.Exp.Ther. 351 359 PMID: 25157087

If you know of a relevant reference for UBP 302, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Kainate Receptor Antagonists

Keywords: UBP 302, UBP 302 supplier, Selective, potent, kainate, antagonists, Glutamate, Kainate, Receptors, iGluR, Ionotropic, UBP302, neurodegeneration, 2079, Tocris Bioscience

3 Citations for UBP 302

Citations are publications that use Tocris products. Selected citations for UBP 302 include:

Randall et al (2011) Fast oscillatory activity induced by kainate receptor activation in the rat basolateral amygdala in vitro. Eur J Neurosci 33 914 PMID: 21255131

Caiati et al (2013) PrPC controls via protein kinase A the direction of synaptic plasticity in the immature hippocampus. J Neurosci 33 2973 PMID: 23407955

Talpalar and Kiehn (2010) Glutamatergic mechanisms for speed control and network operation in the rodent locomotor CpG. Front Neural Circuits 4 PMID: 20844601

Do you know of a great paper that uses UBP 302 from Tocris? Please let us know.

Reviews for UBP 302

There are currently no reviews for this product. Be the first to review UBP 302 and earn rewards!

Have you used UBP 302?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.